vs
Reddit, Inc.（RDDT）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Reddit, Inc.的1.2倍（$772.1M vs $663.0M），Reddit, Inc.净利率更高（30.8% vs 12.7%，领先18.0%），Reddit, Inc.同比增速更快（69.0% vs 5.9%），Reddit, Inc.自由现金流更多（$311.0M vs $161.8M），过去两年Reddit, Inc.的营收复合增速更高（53.6% vs 9.0%）
Reddit是美国知名的社交新闻聚合与论坛类社交媒体平台，注册用户可发布链接、文字帖、图片、视频等各类内容，其他用户可对内容进行点赞或点踩，内容按主题归类到用户创建的子板块中，获赞更高的内容会排在板块前列，热度足够的内容还将展示在全站首页。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
RDDT vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.2倍
$663.0M
营收增速更快
RDDT
高出63.1%
5.9%
净利率更高
RDDT
高出18.0%
12.7%
自由现金流更多
RDDT
多$149.2M
$161.8M
两年增速更快
RDDT
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $663.0M | $772.1M |
| 净利润 | $204.0M | $98.4M |
| 毛利率 | 100.0% | — |
| 营业利润率 | 0.0% | 14.5% |
| 净利率 | 30.8% | 12.7% |
| 营收同比 | 69.0% | 5.9% |
| 净利润同比 | 680.0% | 3.9% |
| 每股收益（稀释后） | $1.01 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RDDTRVTY
| Q1 26 | $663.0M | — | ||
| Q4 25 | $725.6M | $772.1M | ||
| Q3 25 | $584.9M | $698.9M | ||
| Q2 25 | $499.6M | $720.3M | ||
| Q1 25 | $392.4M | $664.8M | ||
| Q4 24 | $427.7M | $729.4M | ||
| Q3 24 | $348.4M | $684.0M | ||
| Q2 24 | $281.2M | $691.7M |
净利润RDDTRVTY
| Q1 26 | $204.0M | — | ||
| Q4 25 | $251.6M | $98.4M | ||
| Q3 25 | $162.7M | $46.7M | ||
| Q2 25 | $89.3M | $53.9M | ||
| Q1 25 | $26.2M | $42.2M | ||
| Q4 24 | $71.0M | $94.6M | ||
| Q3 24 | $29.9M | $94.4M | ||
| Q2 24 | $-10.1M | $55.4M |
毛利率RDDTRVTY
| Q1 26 | 100.0% | — | ||
| Q4 25 | 91.9% | — | ||
| Q3 25 | 91.0% | 53.6% | ||
| Q2 25 | 90.8% | 54.5% | ||
| Q1 25 | 90.5% | 56.5% | ||
| Q4 24 | 92.6% | — | ||
| Q3 24 | 90.1% | 56.3% | ||
| Q2 24 | 89.5% | 55.7% |
营业利润率RDDTRVTY
| Q1 26 | 0.0% | — | ||
| Q4 25 | 31.9% | 14.5% | ||
| Q3 25 | 23.7% | 11.7% | ||
| Q2 25 | 13.6% | 12.6% | ||
| Q1 25 | 1.0% | 10.9% | ||
| Q4 24 | 12.4% | 16.3% | ||
| Q3 24 | 2.0% | 14.3% | ||
| Q2 24 | -11.0% | 12.4% |
净利率RDDTRVTY
| Q1 26 | 30.8% | — | ||
| Q4 25 | 34.7% | 12.7% | ||
| Q3 25 | 27.8% | 6.7% | ||
| Q2 25 | 17.9% | 7.5% | ||
| Q1 25 | 6.7% | 6.4% | ||
| Q4 24 | 16.6% | 13.0% | ||
| Q3 24 | 8.6% | 13.8% | ||
| Q2 24 | -3.6% | 8.0% |
每股收益（稀释后）RDDTRVTY
| Q1 26 | $1.01 | — | ||
| Q4 25 | $1.24 | $0.86 | ||
| Q3 25 | $0.80 | $0.40 | ||
| Q2 25 | $0.45 | $0.46 | ||
| Q1 25 | $0.13 | $0.35 | ||
| Q4 24 | $4.76 | $0.77 | ||
| Q3 24 | $0.16 | $0.77 | ||
| Q2 24 | $-0.06 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.2B | $7.3B |
| 总资产 | $3.5B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RDDTRVTY
| Q1 26 | $1.4B | — | ||
| Q4 25 | $953.6M | $919.9M | ||
| Q3 25 | $911.7M | $931.4M | ||
| Q2 25 | $734.1M | $991.8M | ||
| Q1 25 | $635.7M | $1.1B | ||
| Q4 24 | $562.1M | $1.2B | ||
| Q3 24 | $515.9M | $1.2B | ||
| Q2 24 | $468.0M | $2.0B |
股东权益RDDTRVTY
| Q1 26 | $3.2B | — | ||
| Q4 25 | $2.9B | $7.3B | ||
| Q3 25 | $2.6B | $7.4B | ||
| Q2 25 | $2.4B | $7.6B | ||
| Q1 25 | $2.2B | $7.6B | ||
| Q4 24 | $2.1B | $7.7B | ||
| Q3 24 | $2.0B | $7.9B | ||
| Q2 24 | $1.9B | $7.9B |
总资产RDDTRVTY
| Q1 26 | $3.5B | — | ||
| Q4 25 | $3.2B | $12.2B | ||
| Q3 25 | $2.9B | $12.1B | ||
| Q2 25 | $2.6B | $12.4B | ||
| Q1 25 | $2.4B | $12.4B | ||
| Q4 24 | $2.3B | $12.4B | ||
| Q3 24 | $2.2B | $12.8B | ||
| Q2 24 | $2.1B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $311.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 46.9% | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $868.6M | $509.4M |
8季度趋势，按日历期对齐
经营现金流RDDTRVTY
| Q1 26 | — | — | ||
| Q4 25 | $266.8M | $182.0M | ||
| Q3 25 | $185.2M | $138.5M | ||
| Q2 25 | $111.3M | $134.3M | ||
| Q1 25 | $127.6M | $128.2M | ||
| Q4 24 | $90.0M | $174.2M | ||
| Q3 24 | $71.6M | $147.9M | ||
| Q2 24 | $28.4M | $158.6M |
自由现金流RDDTRVTY
| Q1 26 | $311.0M | — | ||
| Q4 25 | $263.6M | $161.8M | ||
| Q3 25 | $183.1M | $120.0M | ||
| Q2 25 | $110.8M | $115.5M | ||
| Q1 25 | $126.6M | $112.2M | ||
| Q4 24 | $89.2M | $149.8M | ||
| Q3 24 | $70.3M | $125.6M | ||
| Q2 24 | $27.2M | $136.6M |
自由现金流率RDDTRVTY
| Q1 26 | 46.9% | — | ||
| Q4 25 | 36.3% | 21.0% | ||
| Q3 25 | 31.3% | 17.2% | ||
| Q2 25 | 22.2% | 16.0% | ||
| Q1 25 | 32.3% | 16.9% | ||
| Q4 24 | 20.8% | 20.5% | ||
| Q3 24 | 20.2% | 18.4% | ||
| Q2 24 | 9.7% | 19.7% |
资本支出强度RDDTRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.4% | 2.6% | ||
| Q3 25 | 0.4% | 2.6% | ||
| Q2 25 | 0.1% | 2.6% | ||
| Q1 25 | 0.2% | 2.4% | ||
| Q4 24 | 0.2% | 3.4% | ||
| Q3 24 | 0.4% | 3.3% | ||
| Q2 24 | 0.4% | 3.2% |
现金转化率RDDTRVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.06× | 1.85× | ||
| Q3 25 | 1.14× | 2.97× | ||
| Q2 25 | 1.25× | 2.49× | ||
| Q1 25 | 4.88× | 3.03× | ||
| Q4 24 | 1.27× | 1.84× | ||
| Q3 24 | 2.40× | 1.57× | ||
| Q2 24 | — | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RDDT
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
